

Semiannual Treatment of Albendazole Alone is Efficacious for Treatment of Lymphatic Filariasis: A Randomized Open-label Trial in Cote d'Ivoire

Allassane F. Ouattara^{1,2,¶}, Catherine M. Bjerum^{3,¶}, Méité Aboulaye⁴, Olivier Kouadio^{1,2}, Vanga K. Marius⁵, Britt Andersen⁶, Daphne Lew⁷, Charles W. Goss⁷, Gary J. Weil⁶, Benjamin G. Koudou^{1,2}, and Christopher L. King^{3,8,*}

¹ Centre Suisse de Recherche Scientifique en Côte d'Ivoire, 01 BP 1303 Abidjan 01, Côte d'Ivoire.

² Université Nangui Abrogoua, 02 BP 801, Abidjan 02, Côte d'Ivoire

³ Center for Global Health and Diseases, Case Western Reserve University School of Medicine, Cleveland, OH, USA

⁴ Programme National de la Lutte Contre la Schistosomiase, les Geohelminthiases et la Filariose Lymphatique, Abidjan, Côte d'Ivoire

⁵ Université Alassane Ouattara Centre Hospitalier Universitaire de Bouake, Bouaké, Côte d'Ivoire

⁶ Infectious Diseases Division, Department of Medicine, Washington University School of Medicine, St. Louis, Missouri, USA

⁷ Division of Biostatistics, Department of Medicine, Washington University School of Medicine, St. Louis, Missouri, USA

⁸ Veterans Affairs Research Service, Cleveland Veterans Affairs Medical Center, USA

[¶] Joint first authors

*Correspondence to: Christopher L. King, Center for Global Health and Diseases, 10900 Euclid Avenue, Case Western Reserve University School of Medicine, Cleveland, OH, USA 44106, telephone 1 216 368 4817, fax: 1 216 368 4825, cxk21@case.edu.

Summary: This study showed that semiannual treatment with albendazole alone has macrofilaricidal activity that can lead to sustained reductions in microfilaremia, circulating filarial antigenemia, and in adult worm nests in people infected with lymphatic filariasis.

Accepted Manuscript

ABSTRACT

Background

Ivermectin (IVM) plus albendazole (ALB), or IA, is widely used in mass drug administration (MDA) programs that aim to eliminate lymphatic filariasis (LF) in Africa. However, IVM can cause severe adverse events in persons with heavy *Loa loa* infections that are common in Central Africa. ALB is safe in loiasis, but more information is needed on its efficacy for LF. This study compared the efficacy and safety of three years of semiannual treatment with ALB to annual IA in persons with bancroftian filariasis.

Methods

Adults with *Wuchereria bancrofti* microfilaremia (Mf) were randomized to receive either three annual doses of IA (N=52), six semiannual doses of ALB 400mg (N=45), or six semiannual doses of ALB 800mg (N=47). The primary outcome amicrofilaremia at 36 months.

Findings

IA was more effective for completely clearing Mf than ALB 400mg or ALB 800mg (79%, CI 67-91; vs. 48%, CI 32-66 and 57%, CI 41-73, respectively). Mean % reductions in Mf counts at 36 months relative to baseline tended to be greater after IA (98%, CI 88-100) than after ALB 400mg (88%, CI 78-98) and ALB 800mg (89%, CI 79-99) (P=0.07 and P=0.06, respectively). Adult worm nest numbers (assessed by ultrasound) were reduced in all treatment groups. Treatments were well tolerated.

Interpretation

Repeated semiannual treatment with ALB is macrofilaricidal for *W. bancrofti* and leads to sustained reductions in Mf counts. This is a safe and effective regimen that could be used as MDA to eliminate LF in areas ivermectin cannot be used.

Key words: Lymphatic filariasis, albendazole, macrofilaricidal, Cote d'Ivoire

BACKGROUND

Lymphatic filariasis (LF) is a leading cause of preventable disability in the world, and it has been targeted for elimination as a global health problem by 2030 [1]. An estimated 323 million people are at risk for LF in sub-Saharan Africa [1]. Elimination efforts in sub-Saharan Africa utilize annual mass drug administration (MDA) with a combination of ivermectin (IVM) and albendazole (ALB) (IA) have significantly reduced LF in sub-Saharan countries [2, 3]. However, IVM cannot be used in Central African countries where LF is co-endemic with *Loa loa* because of the risk of serious adverse events (AE) in persons with high level *L. loa* microfilaremia (Mf) [4, 5]. In contrast to IVM, ALB has no direct effect on Mf, but it has embryotoxic and macrofilaricidal activity against adult filarial worms. Thus, repeated treatment with ALB alone slowly reduces Mf counts in blood [6, 7]. In 2012 the World Health Organization (WHO) proposed a provisional strategy of MDA with ALB together with integrated vector management to eliminate LF in areas co-endemic for *L. loa* [8], where an estimated 1.4 million are at risk for serious AEs with ivermectin [9]. When the current trial began, there were no data on the efficacy of semiannual treatment with ALB alone for clearing *W. bancrofti* Mf, although semiannual treatment with albendazole paired with ivermectin [10] or DEC [11] showed greater efficacy for clearing Mf compared annual treatment indicating potent benefits of more frequent ALB treatment. Recent community MDA trials with semiannual ALB400mg alone conducted in the Republic of Congo and Democratic Republic of Congo demonstrated significant reductions in circulating filarial antigen levels and in Mf counts [12, 13]. However, these studies did not have a comparator group, and insecticide-treated bednets could have contributed to the observed results. Moreover, a recent review suggested that ALB alone has little ability to clear MF or kill *W. bancrofti* adult worms after a few rounds of treatment [14]. Here we report results of a randomized clinical trial that compared the impact of three years of either semiannual ALB to that of annual IA treatment (the current standard MDA regimen for West Africa) in individuals with *W. bancrofti* infections in Côte d'Ivoire.

METHODS

Study design and participants

This was a randomized, open label, controlled, parallel-group study of participants recruited from Agboville District, Côte d'Ivoire. LF is endemic in Côte d'Ivoire, but *L. loa* is not. The study protocol was approved by institutional review boards (UH Cleveland Medical Center IRB #08-13-13) and (Comité National d'Ethique et de la Recherche, CNER, N: 008/MSLS/CNER/-kp) and registered with ClinicalTrials.gov (NCT02974049). Screening for *W. bancrofti* infection was performed with finger-stick blood samples from 4,910 individuals using a rapid test for CFA (Filariasis Test Strip or FTS, Alere Inc., Waltham, MA, USA). FTS positive individuals had night blood testing for Mf as described below. All participants provided written informed consent and 189 individuals were enrolled (**Figure 1**). Inclusion criteria were ≥ 50 Mf/mL, age 18-70 years, no recent acute illness, and no treatment with ALB or IVM within the last 5 years. Exclusion criteria included a positive pregnancy test; a history of chronic kidney or liver disease, or serum alanine transaminase, aspartate transaminase or creatinine levels >1.5 times the upper limits of normal or severe anemia (blood hemoglobin <7 gm/dL). Persons with onchocerca microfilaridemia or positive Ov16 antibody test were excluded. The protocol was amended to reevaluate participants for presence of Mf and filarial antigen in persons treated with ALB alone at 48 months.

Randomization and masking

Two studies used the same IA treatment control group, but this report only presents data from one of the studies. Results from the other study has been published [15]. A computer-generated block randomization table assigned participants to one of four treatment arms, with three arms reported here as follows: A) Three annual doses of co-administered IVM 200µg/kg (Merck & Co., Kenilworth, NJ, USA) plus ALB400mg (GlaxoSmithKline, Uxbridge, United Kingdom); B) Semiannual ALB400mg alone or C) Semiannual ALB800mg

alone each provided every six months for three years for a total six doses. The study coordinator who distributed medications had sole access to the randomization table. Investigators who evaluated AEs, performed ultrasounds, or read Mf slides were masked to treatment assignments.

Procedures

Enrollment procedures evaluated symptoms, measured vital signs, and performed a physical examination before treatment. This was repeated 24 hours after treatment, and trained village health workers contacted participants daily through day 7 to record and manage AEs. These were scored using a modified version of the National Cancer Institute Common Terminology Criteria for Adverse Events, v4.0. Treatment was directly observed to assure all tablets were swallowed.

Detection of infections

Filarial antigenemia was detected with Filariasis Test Strips according to the manufacturer's instructions. Positive tests were scored semi-quantitatively from negative (0) and 1, 2, and 3 as previously described [16]. Individuals with positive FTS were checked for Mf by membrane filtration of two 1 ml aliquots of venous night blood as previously described [15]. Two microscopists independently read Giemsa-stained filters. A third microscopist read filters with discordant results. Prior to treatment, scrotal ultrasound examinations were performed on men in the supine position using a SonoScape S8 portable ultrasound with a 5-10 MHz linear array transducer (International Diagnostic Devices, Las Vegas, NV). Adult worm nests were identified by worm movement [17, 18] and digitally recorded. Participants with worm nests at baseline were rescanned at 6, 12, 24 and 36 months. The presence or absence of worm nests, the number and location, the maximum diameter, and the degree of

lymphatic vessel dilation were recorded. Worm nests not identified on previous examinations were considered to be new, incident infections.

Outcomes

Primary endpoints were complete clearance of Mf and CFA from blood 36 months post-treatment. The same parameters at 12 and 24 months were secondary endpoints. Other secondary endpoints included mean percent reduction in Mf, reductions in CFA test scores, and percent inactivation of adult filarial worm nests (compared to baseline) at all time points post-treatment.

Statistical analysis

Sample size calculation was based on the following assumptions for the hypothesis that semiannual ALB monotherapy is non-inferior for clearing *W. bancrofti* Mf compared to annual IA administration at 36 months. The margin of equivalence was set at 15%, $\alpha=0.05$, and we assumed that $\geq 70\%$ of persons enrolled would be followed through 36 months. We assumed that three annual doses of IA would achieve complete Mf clearance in 95% of participants at 36 months. A sample of 70 participants in each treatment arm would provide the trial with a power of 80% to test the hypothesis that at least 80% of participants would have complete Mf clearance after six ALB doses. An intention to treat (ITT) analysis was performed for all individuals who were tested at 36 months for the primary outcome assessment.

Baseline sample characteristics between treatment arms, and subsequent Mf and FTS clearance rates were compared using the Chi-squared test and relative risk analysis. A negative binomial generalized estimating equation model (PROC GENMOD in SAS Institute, Cary, NC) compared changes in Mf and worm nest counts across time and between treatment arms. The model included the follow-up time points of 6, 12, 24 and 36 months

and interaction between treatment and time as fixed effects. The model adjusted for baseline Mf levels. An unstructured correlation was used to account for correlation among repeated measurements.

RESULTS

Enrollment, treatment assignment and baseline filariasis test results

Screening of 4,910 adults yielded 189 eligible individuals (all Mf and CFA positive), 144 of whom were randomized to treatment with annual IA, or semiannual ALB400mg or ALB800mg. Participants were enrolled between Feb 5 and Sept 13, 2015. Thirty individuals withdrew from the study after enrollment (10 from IA, 11 from ALB400mg and 9 from ALB800mg arms) and two died of unrelated causes. Baseline demographics, Mf counts, and CFA levels were similar in the three arms (**Table 1**). Participants were mostly men (82%, n=118) because of higher infection prevalence in males and reluctance of women to participate in the treatment trial. Pre-treatment Mf counts ranged from 51 to 2,551 Mf/mL with an overall geometric mean of 193 Mf/mL.

Effects of treatment on microfilaremia

Treatment with IA administered once per year for 3 years cleared Mf in 34%, 26%, 54%, and 79% of participants at 6, 12, 24 and 36 months, respectively (**Table 2**); semiannual ALB cleared Mf more slowly and less completely. ALB400mg cleared Mf in 3%, 14%, 24%, and 48% of participants, and ALB800mg cleared Mf in 5%, 17%, 30% and 57% of participants at the same time points. At 36 months, ALB at both 400mg and 800mg was inferior to IA by -31% and -22%, respectively, which was outside our predefined 15% non-inferiority margin ($P=0.389$ and $P=0.12$).

Changes in Mf counts after treatment were assessed by two methods; percent reduction compared to baseline and absolute decreases in Mf count adjusting for baseline Mf levels using a generalized estimating equation. With respect to the first analysis, twice-yearly treatment with ALB400mg or ALB800mg progressively reduced blood Mf levels to achieve 88% (CI 78,98) and 89% (CI 79,99) mean % reductions in Mf counts at 36 months respectively. These reductions in Mf counts were equivalent between ALB doses ($P=0.98$, 0.75, 0.64, 0.93 at 6, 12, 24 and 36 months, respectively). By contrast, annual IA treatment reduced Mf levels to a much greater extent at interim points, although percent reductions converged at 36 months for all three treatment arms and were not statistically different. The percent reduction in Mf counts from baseline to 36 mo for the IA treatment group was 98% (CI 88,100). **Figure 2** shows absolute reductions in Mf counts using model adjusted Mf values. Microfilaria counts decreased rapidly after the first dose of IA, whereas semiannual ALB alone resulted in slower reductions in Mf counts. Reductions in Mf were similar in all three treatment arms at 36 months.

Effects of treatment on circulating filarial antigenemia

FTS scores significantly decreased by 44%, 50% and 42% in IA, ALB400mg and ALB800mg arms respectively by 12 months (**Figure 3**, $P<0.001$). FTS scores did not decrease further at 24 and 36 months even though participants continued to receive treatment. Few participants completely cleared CFA by 36 months; [4/42(10%) cleared CFA after IA, 2/33(6%) after ALB400mg, and 1/37(3%) after ALB800mg].

Effects of treatment on filarial adult worm nests

Prior to treatment, 62 of 118 (53%) male study participants had motile worm nests in scrotal lymphatics as determined by ultrasound, with 34, 11 and 17 men having detectable worms in the IA, ALB400mg and ALB800mg groups, respectively (**Table 1**). **Table 3** shows a minority of individuals had complete inactivation of all adult worm nests at all time points

that was similar between treatment arms. Of note, after the first one or two doses of ALB, with or without IVM, no further reduction in complete nest inactivation was observed.

Treatment with IA and ALB800mg significantly reduced the number of detectable worm nests at 12 and 24 months without further reduction by 36 months (**Table 4**). ALB400mg failed to significantly reduce worm nest numbers at any time point. However, ALB400mg treatment group had insufficient power to detect reductions in worm nests because relatively few men in that group had worm nests visible at baseline. There was no difference in the reduction in worm nest between treatment arms. The mean diameter of persistently active worm nests and the degree of lymphatic vessel dilatation were not significantly changed at any time point in any arm.

Presence of Microfilaria and Circulating Filarial antigen 48 months after treatment

To assess potential sustained effects of six rounds of ALB, we examined Mf levels and CFA positivity at 48 months (i.e., 18 months after the last ALB treatment, **Table 6**) among individuals willing to participate in the ALB alone treatment arms. The participants in the ALB+IVM arm were not examined. Among the individuals examined at 48 months, Mf clearance increased from 46% at 36 months to 79% at 48 months who had received ALB400mg and from 48% to 78% respectively in those treated with ALB800mg. All but one participant in both arms who was Mf-negative at 36 months remained negative at 48 months. With respect to CFA, 23/24(96%) individuals in the ALB400mg group were positive at 36 months and 15/24(63%) at 48 months. In ALB800mg arm 26/27(96%) were CFA positive at 36 months and 21/27(78%) at 48 months.

Adverse events following treatment

One hundred thirty-three individuals (92%) were evaluated for treatment-associated AEs 24 hours after treatment (**Table 5**). Most AEs were mild (Grade 1) and were more common in the IA arm compared to ALB400mg or ALB800mg arms. Moderate (Grade 2) AEs occurred infrequently, and rates did not differ by treatment group. Headache, fatigue

and muscle aches were the most common AEs reported. There were no severe or serious AEs. Post-treatment fevers and changes in vital signs were uncommon and did not differ between groups. There were no moderate AEs, and few mild AEs were reported between days 2 and 7 post-treatment.

DISCUSSION

This randomized clinical trial demonstrated that six semiannual rounds of ALB alone is safe and effective for treatment bancroftian filariasis. At 36 months after initiation of treatment Mf clearance was similar to the standard treatment with three annual rounds of ivermectin plus ALB. Our data support the WHO recommendation for using ALB alone to treat LF in areas co-endemic for *L. loa*. Albendazole alone demonstrated a macrofilaricidal effect based on reductions in FTS scores and adult worm nests visible by ultrasound. The delayed decline in Mf counts after ALB is consistent with a pure macrofilaricidal (or adult worm sterilizing) effect without a direct effect of ALB on Mf. Albendazole effects on microfilaremia were dose and time-dependent and clearly inferior to IA until the 36 months timepoint. In spite of ALBs inferior performance compared to IA for complete Mf clearance at 36 months, ALB reduced Mf counts by 88-89% relative to baseline values, and those reductions were comparable to that achieved after annual administration of IA [5, 19]. ALB800mg provided no additional efficacy compared to ALB400mg for reducing blood Mf levels.

Treatment with ALB alone decreased CFA and inactivated adult worm nests, consistent with partial killing of adult worms [20, 21]. This macrofilaricidal effect was obvious at 12 months (6 months after the second dose of ALB). Additional doses of ALB produced no further decrease in CFA and decline in adult worm nests by 36 months. This suggests that a subset of adult worms may be relatively resistant to ALB. Progressive reductions in Mf counts over time suggest that albendazole's embryotoxic effect may be more potent than its

macrofilaricidal effect. The embryotoxic effect may be related to inhibition of beta-tubulin polymerization required for cell division in embryos. It is interesting that the effects of ALB were not fully reflected by Mf and FTS results at 36 months. Reexamination of many participants in the ALB alone arms at 48 months (i.e., 18 months after the last ALB dose) showed further reductions in Mf counts with complete Mf and CFA clearance in many participants. Thus, the embryotoxic and macrofilaricidal effects of ALB are greatly delayed compared to the microfilaricidal effect of ivermectin.

Prior studies have shown ALB alone to be macrofilaricidal for *W. bancrofti* when it was given at higher doses and with a longer treatment course. Twice daily dosing of 400mg for 3 weeks killed *W. bancrofti* adult worms, and this reduced Mf counts later. However, the high frequency of AEs observed and the prolonged treatment would be unacceptable for MDA [22, 23]. Another study showed that daily ALB400mg for 7 days was well tolerated and produced an 89% reduction in Mf levels relative to baseline 1 year later [24], but this would be difficult to implement for MDA. In contrast, single dose of ALB400mg treatment produced only slight reductions in Mf and CFA levels at 4 months [25, 26] and at later time points after treatment [27-29]. These results suggest ALB provides a comparatively small contribution to early Mf clearance in annual MDA programs when it is combined with IVM or DEC [14]. However, the effects of ALB on adult worms (and secondarily on Mf) are more potent when the drug is provided as part of repeated rounds of MDA. A community-based MDA program in the Republic of Congo, where ALB400mg was administered twice yearly over a course of three years, showed that 94% of individuals cleared Mf and there was a 73% reduction in CFA prevalence [13]. A re-analysis of these data along with results from a similar study in the Democratic Republic of the Congo showed that individuals who took more doses of ALB showed greater Mf clearance [12, 30]. Results from the clinical trial reported here, which also used semiannual ALB, support results from the community-based studies with similar reductions in Mf counts and FTS scores over a similar time period.

A study limitation was that it was open-labelled which could have biased AE reporting. However, staff evaluating AEs were masked regarding treatment allocation and AE rates were low in all treatment groups. Another study limitation was that most participants were men. This was an advantage for detection of worm nests, but drug efficacy could differ in females. However, prior pharmacodynamic studies of ALB in combination with DEC and IVM indicated that sexual differences in ALB absorption and efficacy are not significant [31]. A third limitation is that the primary endpoint for this study was complete Mf clearance at 36 months. Follow-up data from 48 months suggest that efficacy observed at 36 months in ALB treatment arms was sustained and improved in many participants by 48 months without additional treatment.

These results show semiannual ALB is a safe and effective treatment for LF. It clears Mf more slowly than IA but its efficacy approached that of annual IA at 36 months. Our results support the WHO's recommendation to use semiannual ALB to eliminate LF in areas with significant *L. loa* co-endemicity [8] where LF elimination efforts have lagged because of loiasis.

NOTES

Contributors

All authors contributed substantially to this article. CK, GW, and BK were responsible for study design, and CK, CB, and BA performed literature searches. Data was collected by CB, AO, OK, VM, and BA; data was analyzed and interpreted by CB, AO, MA, GW, BK, CG and CK. The manuscript was written by AO, CB, MA, BA, GW, BK, and CK. All authors approved of the final draft.

Acknowledgements

We gratefully acknowledge participation and cooperation of the study participants and the project staff in Cote d'Ivoire who provided essential help with community engagement and the conduct of the study.

Funding and Conflict of Interests

This work was supported by the Bill and Melinda Gates Foundation [grant number OPPGH 5342].

The funders had no role in the study design, data collection, data analysis, or interpretation of data; in the writing of the manuscript; or in the decision to submit for publication. The corresponding author had full access to all study data and had final responsibility for the decision to publish.

All authors declare that they have no competing interests.

References

1. WHO. Global programme to eliminate lymphatic filariasis: progress report. *Wkly Epidemiol Rec* **2018**; 93(44): 589-604.
2. Biritwum NK, Frempong KK, Verver S, et al. Progress towards lymphatic filariasis elimination in Ghana from 2000-2016: Analysis of microfilaria prevalence data from 430 communities. *PLoS neglected tropical diseases* **2019**; 13(8): e0007115.
3. Dorkenoo MA, de Souza DK, Apetogbo Y, et al. Molecular xenomonitoring for post-validation surveillance of lymphatic filariasis in Togo: no evidence for active transmission. *Parasites & vectors* **2018**; 11(1): 52.
4. Gardon J, Gardon-Wendel N, Demanga N, Kamgno J, Chippaux JP, Boussinesq M. Serious reactions after mass treatment of onchocerciasis with ivermectin in an area endemic for *Loa loa* infection. *Lancet* **1997**; 350(9070): 18-22.
5. Boussinesq M, Gardon J, Gardon-Wendel N, Kamgno J, Ngoumou P, Chippaux JP. Three probable cases of *Loa loa* encephalopathy following ivermectin treatment for onchocerciasis. *Am J Trop Med Hyg* **1998**; 58(4): 461-9.
6. Horton J. Albendazole: a review of anthelmintic efficacy and safety in humans. *Parasitology* **2000**; 121 Suppl: S113-32.
7. Horton J. Albendazole: a broad spectrum anthelmintic for treatment of individuals and populations. *Current opinion in infectious diseases* **2002**; 15(6): 599-608.
8. WHO. Guideline: Alternative mass drug administration regimens to eliminate lymphatic filariasis. Contract No.: WHO/HTM/NTD/PCT/2017.0. Geneva, **2017**.
9. Cano J, Basanez MG, O'Hanlon SJ, et al. Identifying co-endemic areas for major filarial infections in sub-Saharan Africa: seeking synergies and preventing severe adverse events during mass drug administration campaigns. *Parasites & vectors* **2018**; 11(1): 70.
10. Dembele B, Coulibaly YI, Dolo H, et al. Use of high-dose, twice-yearly albendazole and ivermectin to suppress *Wuchereria bancrofti* microfilarial levels. *Clin Infect Dis* **2010**; 51(11): 1229-35.

11. Kar SK, Dwibedi B, Kerketa AS, et al. A randomized controlled trial of increased dose and frequency of albendazole with standard dose DEC for treatment of *Wuchereria bancrofti* microfilarems in Odisha, India. *PLoS neglected tropical diseases* **2015**; 9(3): e0003583.
12. Pion SDS, Chesnais CB, Awaca-Uvon NP, et al. The impact of four years of semiannual treatments with albendazole alone on lymphatic filariasis and soil-transmitted helminth infections: A community-based study in the Democratic Republic of the Congo. *PLoS neglected tropical diseases* **2020**; 14(6): e0008322.
13. Pion SDS, Chesnais CB, Weil GJ, Fischer PU, Missamou F, Boussinesq M. Effect of 3 years of biannual mass drug administration with albendazole on lymphatic filariasis and soil-transmitted helminth infections: a community-based study in Republic of the Congo. *The Lancet infectious diseases* **2017**; 17(7): 763-9.
14. Macfarlane CL, Budhathoki SS, Johnson S, Richardson M, Garner P. Albendazole alone or in combination with microfilaricidal drugs for lymphatic filariasis. *The Cochrane database of systematic reviews* **2019**; 1: CD003753.
15. Bjerum CM, Ouattara AF, Aboulaye M, et al. Efficacy and safety of a single dose of ivermectin, diethylcarbamazine and albendazole for treatment of lymphatic filariasis in Cote d'Ivoire: an open-label, randomized, controlled trial. *Clin Infect Dis* **2019**.
16. Chesnais CB, Missamou F, Pion SD, et al. Semi-quantitative scoring of an immunochromatographic test for circulating filarial antigen. *Am J Trop Med Hyg* **2013**; 89(5): 916-8.
17. Dreyer G, Amaral F, Noroes J, Medeiros Z. Ultrasonographic evidence for stability of adult worm location in bancroftian filariasis. *Transactions of the Royal Society of Tropical Medicine and Hygiene* **1994**; 88(5): 558.
18. Dreyer G, Noroes J, Amaral F, et al. Direct assessment of the adulticidal efficacy of a single dose of ivermectin in bancroftian filariasis. *Transactions of the Royal Society of Tropical Medicine and Hygiene* **1995**; 89(4): 441-3.
19. Boussinesq M, Kamgno J, Pion SD, Gardon J. What are the mechanisms associated with post-ivermectin serious adverse events? *Trends in parasitology* **2006**; 22(6): 244-6.

20. Dreyer G, Addiss D, Noroes J, Amaral F, Rocha A, Coutinho A. Ultrasonographic assessment of the adulticidal efficacy of repeat high-dose ivermectin in bancroftian filariasis. *Tropical medicine & international health : TM & IH* **1996**; 1(4): 427-32.
21. Weil GJ, Lammie PJ, Richards FO, Jr., Eberhard ML. Changes in circulating parasite antigen levels after treatment of bancroftian filariasis with diethylcarbamazine and ivermectin. *The Journal of infectious diseases* **1991**; 164(4): 814-6.
22. Jayakody RL, de Silva C, Weerasinghe W. Treatment of bancroftian filariasis with albendazole: evaluation of efficacy and adverse reactions. *Trop Biome* **1993**; 10: 19-24.
23. Ottesen EA, Ismail MM, Horton J. The role of albendazole in programmes to eliminate lymphatic filariasis. *Parasitology today* **1999**; 15(9): 382-6.
24. Gayen P, Nayak A, Saini P, et al. A double-blind controlled field trial of doxycycline and albendazole in combination for the treatment of bancroftian filariasis in India. *Acta tropica* **2013**; 125(2): 150-6.
25. Addiss DG, Beach MJ, Streit TG, et al. Randomised placebo-controlled comparison of ivermectin and albendazole alone and in combination for *Wuchereria bancrofti* microfilaraemia in Haitian children. *Lancet* **1997**; 350(9076): 480-4.
26. Beach MJ, Streit TG, Addiss DG, Prospere R, Roberts JM, Lammie PJ. Assessment of combined ivermectin and albendazole for treatment of intestinal helminth and *Wuchereria bancrofti* infections in Haitian schoolchildren. *Am J Trop Med Hyg* **1999**; 60(3): 479-86.
27. Dunyo SK, Nkrumah FK, Simonsen PE. Single-dose treatment of *Wuchereria bancrofti* infections with ivermectin and albendazole alone or in combination: evaluation of the potential for control at 12 months after treatment. *Transactions of the Royal Society of Tropical Medicine and Hygiene* **2000**; 94(4): 437-43.
28. Dunyo SK, Nkrumah FK, Simonsen PE. A randomized double-blind placebo-controlled field trial of ivermectin and albendazole alone and in combination for the treatment of lymphatic filariasis in Ghana. *Transactions of the Royal Society of Tropical Medicine and Hygiene* **2000**; 94(2): 205-11.

29. Ismail MM, Jayakody RL, Weil GJ, et al. Efficacy of single dose combinations of albendazole, ivermectin and diethylcarbamazine for the treatment of bancroftian filariasis. *Transactions of the Royal Society of Tropical Medicine and Hygiene* **1998**; 92(1): 94-7.
30. Campillo JT, Awaca-Uvon NP, Missamou F, et al. Results from two cohort studies in Central Africa show that clearance of *Wuchereria bancrofti* infection after repeated rounds of mass drug administration with albendazole alone is closely linked to individual adherence. *Clin Infect Dis* **2020**.
31. Edi C, Bjerum CM, Ouattara AF, et al. Pharmacokinetics, safety, and efficacy of a single co-administered dose of diethylcarbamazine, albendazole and ivermectin in adults with and without *Wuchereria bancrofti* infection in Cote d'Ivoire. *PLoS neglected tropical diseases* **2019**; 13(5): e0007325.

Accepted Manuscript

Table 1. Characteristics of trial participants at baseline

Characteristics	IA (N=52)	ALB 400mg (N=45)	ALB 800mg (N=47)
Age, median (years)	35 (19)	40 (20)	39 (21)
(IQR) [†]			
Male sex (%)	46 (88%)	33 (73%)	39 (83%)
Geometric mean Mf count, Mf/mL	190	177	204
(range)	(51-1,065)	(56-1,050)	(52-2,251)
Men with worm nests/number examined (%)	34/42 (80%)	11/27 (41%)	17/31 (54%)
Mean worm nests*	2.5	2.3	3.2
(range)	(1-6)	(1-4)	(1-8)
FTS score [¶]	2.8±0.5	2.8±0.5	2.7±0.4

[†]Interquartile range.

*In men with one or more worm nests detected by ultrasound.

[¶] Average FTS score±SD of 1, 2 or 3.

Table 2. Proportion of individuals with complete Mf clearance after LF treatment

Treatment Group	Characteristic	Months Post Initiation of Treatment			
		6	12	24	36
IVM/ALB (IA) [¶]	No. of participants	44	42	39	42
	Participants with complete Mf clearance*	15	11	21	33
	% with complete Mf clearance	34%	26%	54%	79%
	(95% CI) [§]	(20,48)	(13,39)	(38,70)	(67,91)
ALB 400mg x 6	No. of participants	39	36	34	33
	Participants with complete Mf clearance	1	5	8	16
	% with complete Mf clearance	3%	14%	24%	48%
	(95% CI)	(0,8)	(3,25)	(10,38)	(32,66)
	P-value (chi-square compared to IA x 3)	<0.001	0.262	0.010	0.008
	Risk ratio vs. IA x 3	1.5	1.2	1.7	2.4
	(95% CI)	(1.2,1.8)	(0.9,1.5)	(1.1,2.4)	(1.2,4.7)
	P-value	0.0005	0.175	0.011	0.005
ALB 800mg x 6	No. of participants	40	41	37	37
	Participants with complete Mf clearance	2	7	11	21
	% with complete Mf clearance	5%	17%	30%	57%

(95% CI)	(0,12)	(6,29)	(10,38)	(41,73)
P-value (chi-square compared to IA x 3)	<0.001	0.426	0.011	0.053
Risk ratio vs. IA x 3	1.4	1.1	1.5	2.0
(95% CI)	(1.2,1.8)	(0.9,1.4)	(1.0,2.3)	(1.0,4.0)
P-value	0.0014	0.316	0.039	0.045

[§] CI denotes Confidence Interval using binomial “exact” calculation.

[¶] IA denotes IVM plus ALB.

* Mf, microfilaria.

Table 3. Participants with inactivation of all detectable worm nests after treatment

Treatment Group and Outcomes	Months after Initial Treatment			
	6	12	24	36
IA administered annually				
for 3 years				
Participants with worm nests				
(no.)*	28	28	27	25
Participants with complete				
inactivation of all worm nests	5	9	11	8
% complete inactivation	18%	32%	41%	32%
(95%, CI)	(4,30)	(15,47)	(25,63)	(14,50)
ALB 400mg x 6				
Participants with worm nests				
(no.)*	10	9	8	9
Participants with complete				
inactivation of all worm nests	2	2	1	2
% complete inactivation	20%	22%	13%	22%
(95%, CI)	(0,45)	(0,49)	(0,36)	(0,49)
P-value	1.0	0.69	0.21	0.69
ALB 800mg x 6				
Participants with worm nests				
(no.)*	15	14	12	9

Participants with complete

inactivation of all worm nests	2	3	2	3
% complete inactivation	13%	21%	17%	33%
(95%, CI)	(0,30)	(0,42)	(0,39)	(5,65)
P-value	1.00	0.69	0.15	1.00

*Only data from participants with worm nests detected by ultrasound at baseline are included in this table.

Accepted Manuscript

Table 4. Adjusted mean numbers of worm nests (95% CI) at baseline and following treatment*

Months post initiation of treatment	ALB+IVM	ALB 400mg alone	ALB 800mg alone
0	2.31 (1.76, 3.03)	2.14 (1.31, 3.5)	3.01 (2.1, 4.31)
6	2.39 (1.79, 3.19)	1.84 (1.07, 3.16)	3.06 (2.11, 4.45)
12	1.22 (0.85, 1.77)	1.69 (0.94, 3.03)	1.48 (0.92, 2.39)
24	1.00 (0.67, 1.51)	1.64 (0.89, 3.04)	1.23 (0.71, 2.15)
36	1.12 (0.75, 1.67)	1.9 (1.09, 3.32)	1.22 (0.65, 2.28)

* Table 4 only includes data from men with detectable worm nests at baseline. There were no significant differences across treatment arms ($p=0.3$ or greater at each time point). There was a significant decrease in worm nests in the IA and ALB 800mg treatment arms between baseline and 12, 24 and 36 months post initiation of treatment ($p=0.002$, $p<0.001$ and $p<0.001$ for IA respectively, and $p=0.005$, $p=0.002$ and $p=0.006$ for ALB800mg) but not ALB400mg ($p=0.5$, $p=0.4$ and $p=0.7$). A negative binomial generalized estimating equation model that included random effects for subjects was used to calculate means, confidence intervals and p-value.

Table 5. Adverse events (AEs) following LF treatment[¶]

	IA (N=48)	ALB 400mg (N=43)	ALB 800mg (N=42)
At least one AE (%)	19 (39.6)	7 (16.3)**	11 (26.2)
Individuals with two or more AEs (%)	7 (14.6)	2 (4.7)	1 (2.4)
Severe or Serious AEs	0	0	0
Fever ≥ 38°C (%)	3 (6.3)	1 (2.3)	0
Hemodynamic changes	1	2	1
Overall grade 1 AEs (total)	32	7*	12*
Overall grade 1 AEs (subjective only)	20	5	9
Overall Grade 2 AEs (total) [¶]	5	2	0
Grade 2 Fever ≥ 38.5°C	2 (4.2)	1 (2.3)	0
Grade 2 Fatigue	0	1 (2.3)	0
Grade 2 Nausea/vomiting	1 (2.1)	0	0

Grade 2 Muscle ache	1 (2.1)	0	0
Grade 2 Lightheaded	1 (2.1)	0	0

† Compared to pre-treatment clinical assessments, any new or worsening symptoms, changes in vital signs or new abnormal physical examination findings were considered to be drug-related AEs.

* $P < 0.05$ and ** $P < 0.01$ compared to IA arm

† 4 individuals had 1 Grade 2 event, 1 individual had 3 Grade 2 events

Accepted Manuscript

Table 6. Microfilaria (Mf) levels and circulating filarial antigen (CFA) positivity changes from 36 to 48 months after initiation of treatment.

Albendazole 400mg arm

			CFA*	CFA*
	Baseline Mf/ml	36 mos Mf/ml	48 mos Mf/ml	(36 mos) (48 mos)
	332	465	55	2 2
	529	282	113	3 3
	215	250	0	2 3
	968	193	221	3 2
	95	119	0	2 1
	391	32	0	2 0
	106	16	5	3 3
	944	14	0	2 1
	274	11	10	2 2
	83	1	0	2 1
	337	1	0	2 1
	274	1	0	2 1
	171	1	0	2 2
	222	0	0	2 0
	79	0	0	1 1
	109	0	0	0 0
	614	0	0	3 2
	209	0	0	3 0

55	0	0	1	0
644	0	0	1	0
210	0	0	2	1
76	0	0	1	0
203	0	0	1	0
132	0	0	2	0
N negative	11/24 (46%)	19/24 (79%)	1/24 (4%)	9/24 (38%)

(% cleared)

Albendazole 800mg arm

Baseline	36 mos	48 mos	CFA*	CFA*
Mf/ml	Mf/ml	Mf/ml	(36 mos)	(48 mos)
2050	611	13	3	3
976	268	33	3	3
177	86	44	3	2
518	63	0	3	2
860	62	97	2	3
519	33	5	1	2
86	29	0	1	2
168	28	0	1	1
221	22	0	3	3
70	7	0	2	1
445	7	0	3	3

97	6	0	1	0
91	2	0	1	0
61	1	0	2	1
1050	0	0	2	1
470	0	0	1	1
70	0	0	1	0
307	0	0	3	0
116	0	4	0	1
70	0	0	2	2
110	0	0	2	1
59	0	0	1	1
575	0	0	1	0
89	0	0	1	0
74	0	0	2	1
73	0	0	1	1
210	0	0	1	1
N negative	13/27 (48%)	21/27 (78%)	1/27 (4%)	6/27 (22%)
(% cleared)				

*CFA is measured using the semi-quantitative filarial test strip (FTS) described in the materials and methods section.

Figure Legends

Figure 1. CONSORT diagram shows screening, randomization, and follow-up. Participants enrolled in each treatment arm were retested for LF infection (FTS, Mf and presence of worm nests by ultrasound in men with nests at baseline) at 6, 12, 24 and 36 months. Note that the treatment arm IVM+DEC+ALB is not included in this report; it was part of a separate study that used the same IA comparator arm [15].

Figure 2. Comparison of adjusted mean Mf counts (95% CI) in the three treatment groups using a negative binomial generalized estimating equation. Treatment with IA was superior for reducing Mf counts compared to ALB 400mg at 6, 12, and 24 but not at 36 months ($P < 0.001, 0.027, 0.03, 0.067$, respectively). For ALB 800mg compared with IA, P -values at the same time points were $P < 0.001, 0.029, 0.08$ and 0.064 . There were no significant differences at any time point for reductions in Mf counts after ALB 400mg or ALB 800mg (see text for P values). Numbers of participants for each time point are shown in Table 2.

Figure 3. Mean (\pm SD) FTS score at each time point following treatment. At 12, 24 and 36 months, FTS scores were significantly lower than baseline for all three treatment groups ($P < 0.001$ by the Mann Whitney U test) and equivalent across individual time points for each group ($P > 0.2$, all time points).

Figure 1




Figure 2




Figure 3

